Treating leukemia at the risk of inducing severe anemia.
Treating leukemia at the risk of inducing severe anemia.
复制标题
治疗白血病有诱发严重贫血的风险。
DOI：
10.1016/j.exphem.2016.01.004
复制
发表时间：
2016-05
影响因子：
2.6
通讯作者：
Feng GS
中科院分区：
文献类型：
--
作者：
Chen WS;Zhu HH;Feng GS
贫血是在接受化疗或旨在阻断特定致癌信号通路的药物的癌症患者中经常观察到的不良反应，尽管对其潜在机制知之甚少。首次在线发表的一篇文章（Zhu HH，Luo X，Zhang K，et al. Proc Natl Acad Sci USA 2015;112：13342-13347）提供了表明细胞类型特异性途径串扰可能是要考虑的重要机制的数据。Shp 2和Pten是两个主要的细胞质信号通路调节因子，在骨髓增殖和白血病发生中相互对抗，但在促进红细胞生成中相互合作。因此，Shp 2的基因消融或药理学抑制抑制Pten损失的致白血病作用，但同时诱导血细胞中Pten缺乏的小鼠严重贫血。
Anemia is a frequently observed adverse effect in cancer patients who receive chemotherapy or drugs designed to block specific oncogenic signaling pathways, although the underlying mechanisms are poorly understood. An article first published online (Zhu HH, Luo X, Zhang K, et al. Proc Natl Acad Sci USA 2015;112:13342–13347) presented data indicating that cell type-specific pathway cross-talk is likely an important mechanism to consider. Shp2 and Pten, two master regulators of central cytoplasmic signaling pathways, oppose each other in myeloproliferation and leukemogenesis, but cooperate in promoting erythropoiesis. Thus, genetic ablation or pharmacologic inhibition of Shp2 suppresses the leukemogenic effect of Pten loss, yet simultaneously induces severe anemia in mice with Pten deficiency in blood cells.